Allergen-specific sublingual immunotherapy for respiratory allergy

Area of Science:

• Allergy and Immunology
• Respiratory Medicine
• Pharmacology

Background:

• Allergen-specific immunotherapy is a biological response modifier for respiratory allergies.
• Subcutaneous immunotherapy (SCIT) has established efficacy but carries risks of severe adverse events.
• Novel administration routes, including sublingual immunotherapy (SLIT), have been developed for improved safety.

Purpose of the Study:

• To review the clinical efficacy and safety of sublingual immunotherapy (SLIT) for respiratory allergy treatment.
• To compare SLIT with traditional subcutaneous immunotherapy (SCIT).
• To assess SLIT's role as a viable alternative in allergy management.

Main Methods:

• Review of existing knowledge on SLIT efficacy and safety.
• Analysis of 18 randomized controlled clinical trials investigating SLIT.
• Inclusion of data from post-marketing surveillance studies.

Main Results:

• SLIT demonstrated clinical efficacy in 16 of 18 trials, improving symptoms and reducing medication needs for asthma and rhinitis.
• SLIT exhibits a satisfactory safety profile in both adults and children, with manageable gastrointestinal side effects.
• No severe systemic adverse events have been reported with SLIT.

Conclusions:

• SLIT is a safe and effective alternative to SCIT for respiratory allergies, with good patient acceptance, especially in children.
• SLIT is a self-administered treatment suitable for home use.
• Further research is needed on SLIT's mechanisms of action and long-term preventive effects.